• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Australia·Consumer Cyclical·S66.AX
Share

Star Combo Pharma Limited Stocks

A$ 0.14Last Updated 20.10.2026

Issuer Rating

2/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

A$ 13.13M

A$ 0.14
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Star Combo Pharma Limited is involved in the production and supply of health foods and dietary supplements across Australia and China. The company's activities are organized into two primary divisions: Star Combo and Austoyou Retail. It manages the full spectrum of natural health supplements and skincare products, encompassing their development, manufacturing, promotion, and sale. Distribution channels include a dedicated e-commerce platform for health-conscious consumers in China, alongside two brick-and-mortar retail stores situated in Sydney. Founded in 2004, Star Combo Pharma Limited's main office is located in Smithfield, Australia.

Company Valuation

Greatly overvalued
1/7

From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. Specifically, the stock is 'expensive' on P/E, overvalued

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

21.10.2026 22:20

Berkshire Hathaway shares hit a new record high—for the first time since Buffett announced his retirement

21.10.2026 22:08

A Left or Right Turn: What Investors Are Watching Ahead of the French Presidential Election

21.10.2026 21:10

Shares of Ray-Ban had their best day since 2008. Should you buy them?

21.10.2026 20:20

The Old World on New Chips: How Nvidia Is Driving the Industrial Revolution in Europe

21.10.2026 20:13

Getty Images has filed for bankruptcy. It will become privately owned.

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026